Dapsone in the treatment of cutaneous lupus erythematosus

Dermatology

Volumn 172, Issue 4, 1986, Pages 214-217

  Lindskov, Rune ^a   Reymann, Flemming ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

Cutaneous lupus erythematosus; Dapsone; Discoid lupus erythematosus; Systemic treatment

Indexed keywords

CORTICOSTEROID; DAPSONE; HYDROXYCHLOROQUINE;

ADVERSE DRUG REACTION; CLINICAL ARTICLE; DIGESTIVE SYSTEM; DISCOID LUPUS ERYTHEMATOSUS; DRUG EFFICACY; DRUG THERAPY; DYSPEPSIA; GASTROINTESTINAL TOXICITY; HUMAN; INTOXICATION; METHEMOGLOBINEMIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; SKIN LUPUS ERYTHEMATOSUS; SKIN TOXICITY; THERAPY; VERTIGO;

ADULT; AGED; CLINICAL TRIALS; COMPARATIVE STUDY; DAPSONE; FOLLOW-UP STUDIES; HUMAN; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, DISCOID; MIDDLE AGE; TIME FACTORS;

EID: 0022633559     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000249338     Document Type: Article

References (18)

1. Beiguelman, B.; Pisani, R.C.B.: Effect of DDS on phytohemagglutin in-induced lymphocyte transformation. Int. J. Lepr. 42: 412-415 (1974).
2. Bernstein, H.N.: Chloroquine ocular toxicity. Surv. Ophthal. 12:415-447 (1967).
3. Coburn, P.R.; Shuster, S.: Dapsone and discoid lupus erythematosus. Br. J. Derm. 106: 105-106 (1982).
4. Goldman, L.; Cole, D.P.; Preston, R.H.: Chloroquine diphosphate in treatment of discoid lupus erythematosus. J. Am. med. Ass. 152: 1428-1429 (1953).
5. Grosshans, E.; Genevieve, I.: Thalidomide therapy for inflammatory dermatoses. Int. J. Derm. 23:598-602 (1984).
6. Highet, A.S: Urticarial vasculitis resembling systemic lupus erythematosus: efficacy of prednosone and dapsone combined. Br. J. Derm, 102: 358-360 (1980).
7. Lang, P.G.: Sulfones and sulfonamides in dermatology today. J. Am. Acad. Derm. 1: 479-492 (1979).
8. Matthews, C.N.A.; Saihan, E.M.; Warin, R.P.: Urticaria-like lesions associated with systemic lupus erythematosus: response to dapsone. Br. J. Derm. 99: 455-457 (1978).
9. McCormack, L.S.; Elgart, M.L.; Turner, M.LC: Annular subacute cutaneous lupus erythematosus responsive to dapsone, J. Am. Acad. Derm. 11: 397-401 (1984).
10. Mier, P.D.; Van Den Hurk, J.M.A.: Inhibition of lysosomal enzymes by dapsone. Br. J. Derm. 93: 471–472 (1975)
11. Mikkelscn, J.: Øjenkomplikationer ved behandling med antimalariamidler i dermatologien. Ugeskr. Læg. 141: 2316-2318 (1979).
12. Miyachi, Y.; Niwa, Y.: Effects of KJ, colchicine and dapsone on the generation of PML-derived oxygene intermediates. Br. J. Derm. 107: 209-214 (1982).
13. Page, F.: Treatment of lupus erythematosus with mepacrine. Lancet ii: 755-758 (1951).
14. Plewig, G.; Schopf, E.: Antiinflammatory effects of antimicrobial agents: an in vivo study. J. invest. Derm. 65. 532-536 (1975).
15. Ruzicka, T.; Goerz, G.: Systemic lupus erythematosus and vasculitis urticaria. Effect of dapsone and complement levels. Dermatologica 162: 203-205 (1981a).
16. Ruzicka, T.; Goerz, G.: Dapsone in the treatment of lupus erythematosus. Br. J, Derm. 104:53-56 (1981b).
17. Tanenbaum, L.; Tufanelli, D.L.: Antimalarial agents. Chloroquine. hydroxychloroquine, and quinacrine. Archs Derm. 116: 587-591 (1980).
18. Vandersteen, P.R.; Fargo, N.D.; Jordon, R.E.: Dermatitis herpetiformis with discoid lupus erythematosus. Archs Derm. 110: 95-98 (1974).